CDK2 inhibitors induce RB-independent tumor suppression in CDK4/6 inhibitor-resistant HR+/HER2- breast cancer, with disease stabilization observed in patients.
- Open access
Advanced Breast Cancer Therapies
Moving in bioRxiv, Blood, Cancer Research, eLife, Genome Research, Nature Cancer, Nature Chemical Biology.
- Moved this week
- 0
Rebuilt
Moved this week
Nothing in this area has moved yet this week.
Latest in Advanced Breast Cancer Therapies
Newest first · last 60 days
Genomic features controlling ESR1 binding and activity differ between endometrial and breast cancer, with SOX17 uniquely regulating ESR1 in endometrial cancer.
- Open access
Heterogeneity in protein signalling networks, especially reaction coefficients, drives adaptive resistance to CDK4/6 and oestrogen receptor inhibitors, as shown by MDN modelling.
- Open access
- 1 cites
Follow this area in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1746
- Environ Res485
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ205
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- Curr Biol116
- J Exp Bot115
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4